Unknown

Dataset Information

0

Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.


ABSTRACT:

Objective

The Diabetes Care Protocol (DCP), a multifaceted computerized decision support diabetes management intervention, reduces cardiovascular risk of type 2 diabetic patients. We performed a cost-effectiveness analysis of DCP from a Dutch health care perspective.

Research design and methods

A cluster randomized trial provided data of DCP versus usual care. The 1-year follow-up patient data were extrapolated using a modified Dutch microsimulation diabetes model, computing individual lifetime health-related costs, and health effects. Incremental costs and effectiveness (quality-adjusted life-years [QALYs]) were estimated using multivariate generalized estimating equations to correct for practice-level clustering and confounding. Incremental cost-effectiveness ratios (ICERs) were calculated and cost-effectiveness acceptability curves were created. Stroke costs were calculated separately. Subgroup analyses examined patients with and without cardiovascular disease (CVD+ or CVD- patients, respectively).

Results

Excluding stroke, DCP patients lived longer (0.14 life-years, P = NS), experienced more QALYs (0.037, P = NS), and incurred higher total costs (euro 1,415, P = NS), resulting in an ICER of euro 38,243 per QALY gained. The likelihood of cost-effectiveness given a willingness-to-pay threshold of euro 20,000 per QALY gained is 30%. DCP had a more favorable effect on CVD+ patients (ICER = euro 14,814) than for CVD- patients (ICER = euro 121,285). Coronary heart disease costs were reduced (euro-587, P < 0.05).

Conclusions

DCP reduces cardiovascular risk, resulting in only a slight improvement in QALYs, lower CVD costs, but higher total costs, with a high cost-effectiveness ratio. Cost-effective care can be achieved by focusing on cardiovascular risk factors in type 2 diabetic patients with a history of CVD.

SUBMITTER: Cleveringa FG 

PROVIDER: S-EPMC2809259 | BioStudies | 2010-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6226178 | BioStudies
2014-01-01 | S-EPMC3898909 | BioStudies
2021-01-01 | S-EPMC7898389 | BioStudies
2014-01-01 | S-EPMC4245224 | BioStudies
2021-01-01 | S-EPMC7943717 | BioStudies
2020-01-01 | S-EPMC7774969 | BioStudies
2019-01-01 | S-EPMC6427179 | BioStudies
2020-01-01 | S-EPMC7493170 | BioStudies
1000-01-01 | S-EPMC5018997 | BioStudies
2015-01-01 | S-EPMC4510785 | BioStudies